TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03635047

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
Study: NCT02965820

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Subject's habitual contact lens brand worn in a daily wear modality for 30 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
Study: NCT02806349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: herb

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac-glucomannan fiber blend
Description: Blend of 2 viscous fibers: konjac mannan and xanthan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Fiber matched control for intervention (corn starch and wheat bran)
Study: NCT03729544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen computerized decision support alert
Description: On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
Study: NCT00607737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 3 cutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 3 cutaneous injections
Study: NCT03361436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT03198351

Intervention type: DRUG
Intervention: Teriflunomide (HMR1726)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04557332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On the Dot Mobile app
Description: On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
Study: NCT00082446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group E will receive sterile saline placebo for injection via scarification on day 112.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
Study: NCT00513461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Description: Given PO
Study: NCT01895270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine extended release formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of microcrystalline cellulose.
Study: NCT00513461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT02638831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
Study: NCT02375893

Intervention type: OTHER
Intervention: No intervention
Description: Collecting blood and feces samples
Study: NCT02638831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
Study: NCT01190683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol and calcium carbonate
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol and calcium carbonate
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
Study: NCT02375893

Intervention type: OTHER
Intervention: Healthy subject
Description: Collecting blood and feces samples
Study: NCT04189939

Intervention type: OTHER
Intervention: clinical assessments
Description: Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):
Study: NCT01190683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol and calcium carbonate
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose placebo
Description: similar number of granules and tablets as active group
Study: NCT01694290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemical Cold Pack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemical Cold Pack
Study: NCT04094987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inter-fascial pressure
Description: The pressure between the fascia and the pressure line added to the catheter tip will be measured.
Study: NCT04163133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two days later trigger than regular timing
Description: During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
Study: NCT01190683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
Study: NCT01399463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty performed via Paclitaxel Eluting Balloon catheter
Study: NCT01190683

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
Study: NCT03361436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01531452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1,repeated q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s1
Description: 80mg/m2/d, d1-14,repeated q21d
Study: NCT00916032

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Description: Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Description: Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
Study: NCT00453986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose
Study: NCT01190683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactose granules and tablets
Description: one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
Study: NCT00453986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose
Study: NCT01399463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty via DES
Description: Angioplasty performed via commonly used Drug Eluting Stents
Study: NCT00453986

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One intramuscular dose
Study: NCT00303862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03281473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 1
Description: PEEP titration according to transpulmonary-end-expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 1
Description: PEEP titration according to transpulmonary-end-expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 2
Description: PEEP titration according to chest wall elastance measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy 2
Description: PEEP titration according to chest wall elastance measurement
Study: NCT01806987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
Study: NCT01459861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canal Block and Capsular Injection
Description: Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block with Tibial Nerve Block
Description: Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
Study: NCT04209946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Less Invasive Surfactant Administration LISA
Description: Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure CPAP
Description: Infant will remain on CPAP Therapy during spontaneous respirations
Study: NCT04507386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND for health
Description: The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
Study: NCT01824251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study: NCT00794183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device settings
Description: Comparision of A-V delay settings
Study: NCT03766022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo dental implant Alpha Bio Tec. Ltd.
Description: Neo dental implant is used to restore missing teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neo dental implant Alpha Bio Tec. Ltd.
Description: Neo dental implant is used to restore missing teeth
Study: NCT05260996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot Group
Description: 12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
Study: NCT00583986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI with top mounted actuation indicator
Description: Levalbuterol HFA MDA with top mounted actuation indicator
Study: NCT00513461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03477253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
Study: NCT00513461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02390531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Varying dosages in 10µl
Study: NCT03619460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric extraction
Description: Only Piezoelectric device will be used for surgical wisdom teeth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional extraction
Description: Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
Study: NCT00794183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device settings
Description: Comparision of A-V delay settings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device settings
Description: Comparision of A-V delay settings
Study: NCT00992069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Oral dose of 600 mg daily, taken in the evening
Study: NCT03973411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic ondansetron
Description: Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
Study: NCT00992069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: Single oral dose of 400 mg in the morning
Study: NCT03973411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pacients will receibe standard spinal anesthesia
Study: NCT05170152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography-guided injection
Description: ultrasonography-guided injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pullae A1 release
Description: ultrasonography-guided pullae A1 release
Study: NCT02430649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT01644292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC WheelS
Description: EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
Study: NCT00563641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very early surfactant and bubble NCPAP
Description: For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bubble NCPAP
Description: Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria.
Study: NCT01780038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receipt of Genetic Results
Description: Participants will receive the results of genotyping for RS1051730
Study: NCT04022967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: One daily tablet (50mg) during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir boosted with ritonavir
Description: One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir
Description: One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: One daily tablet (300mg) during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: One daily tablet (300mg) during 96 weeks